GlassScriptPhysician profile
Caroline A Schulenberg
NPI 1770140824
$5,954.13
in general payments reported to CMS, 2019-2025
33 companies · $1,725 in 2025
The $1,725 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $893 · 2022: $1,382 · 2023: $1,075 · 2024: $879 · 2025: $1,725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,678.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,579.78 | 2022-2025 | Vemlidy, Livdelzi, Epclusa |
| Abbvie INC. | $675.40 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $361.92 | 2021-2025 | Entyvio |
| Ipsen Biopharmaceuticals, INC | $252.48 | 2025 | Bylvay, Iqirvo |
| Genzyme Corporation | $249.87 | 2022-2025 | |
| Janssen Biotech, INC. | $232.83 | 2021-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $223.01 | 2021-2025 | Xifaxan |
| Csl Behring | $220.70 | 2021 | |
| Alexion Pharmaceuticals, INC. | $206.61 | 2022 | |
| Inari Medical, INC. | $188.16 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Mallinckrodt Hospital Products INC. | $149.20 | 2025 | Terlivaz |
| Orphalan INC | $148.24 | 2024-2025 | Cuvrior |
| Janssen Scientific Affairs, LLC | $139.46 | 2025 | |
| Shionogi INC | $125.00 | 2021 | |
| Medical Device Business Services, INC. | $124.99 | 2023 | Stratafix |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $122.68 | 2023 | |
| Qol Medical, LLC | $119.40 | 2021-2023 | Sucraid |
| Madrigal Pharmaceuticals | $119.22 | 2024-2025 | Resmetirom, Rezdiffra |
| Pfizer INC. | $106.36 | 2021-2024 | |
| Optinose US, INC. | $104.48 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $79.91 | 2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $72.01 | 2021-2025 | Ocaliva |
| Biofire Diagnostics, LLC | $71.77 | 2021 | |
| Biomerieux INC | $71.77 | 2021 | |
| Jazz Pharmaceuticals INC. | $39.60 | 2022 | |
| Novo Nordisk INC | $24.51 | 2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $22.84 | 2024 | Voquezna |
| Braintree Laboratories, INC. | $21.74 | 2022 | |
| Fresenius Kabi USA, LLC | $21.07 | 2024 | Idacio |
| Celgene Corporation | $20.97 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $20.92 | 2024 | |
| Ardelyx, INC. | $20.72 | 2025 | Ibsrela |
| Amgen INC. | $16.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Schulenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.